Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) (NCT06467435) | Clinical Trial Compass
TerminatedPhase 1
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
Stopped: Low enrollment status
United States4 participantsStarted 2024-11-06
Plain-language summary
The study is comprised of two cohorts. Cohort 1 will examine pharmacokinetics of K9 in 3 healthy volunteers over 24 hours. This cohort has been completed. Cohort 2 will involve up to 10 patients with TED. Patients will receive oral K9 BID for up to 24 weeks and will be followed up to a total of 26 weeks with a primary endpoint of safety.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Cohort 1
* Subject is willing and able to receive treatment and complete corresponding assessments as required by the protocol
Cohort 2
* Diagnosed with Thyroid Eye Disease (TED).
* Symptomatic TED diagnosed no more than 9 months earlier.
* Clinical Activity Score ≥ 3 (on 7 point scale) for the worse eye.
* Subject is willing and able to receive treatment and complete corresponding assessments as required by the protocol.
Exclusion Criteria:
Cohort 1
* Body weight less than 55 kg.
* History of any clinically significant medical disorders the principal investigator considers exclusionary, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease.
* Females who are pregnant, nursing, planning a pregnancy or who are of childbearing potential not using a reliable method of contraception.
* History or current evidence of hypersensitivity to any components of the study medication, as assessed by the investigator.
* Participation in any systemic experimental treatment or any other systemic investigational new drug within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of study treatment. Clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets…
What they're measuring
1
Adverse Events
Timeframe: 26 weeks
2
plasma concentrations of K9
Timeframe: Pharmacokinetic samples collected pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, and 24 hours after dosing